(NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed ... program for the treatment of Generalized Anxiety Disorder. We have ...
This theoretical study makes a useful contribution to our understanding of a subtype of type 2 diabetes – ketosis-prone diabetes mellitus (KPD) – with a potential impact on our broader understanding ...